Cara Therapeutics, Inc. – NASDAQ:CARA
Founder-led company
Cara Therapeutics stock price today
$5.4
+5.02
+1328.47%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Cara Therapeutics stock price monthly change
+7.14%
month
Cara Therapeutics stock price quarterly change
+7.14%
quarter
Cara Therapeutics stock price yearly change
-42.74%
year
Cara Therapeutics key metrics
Market Cap | 22.96M |
Enterprise value | 177.95M |
P/E | -2.86 |
EV/Sales | 4.25 |
EV/EBITDA | -2.08 |
Price/Sales | 5.72 |
Price/Book | 1.51 |
PEG ratio | -0.33 |
EPS | -2.25 |
Revenue | 16.93M |
EBITDA | -120.06M |
Income | -122.54M |
Revenue Q/Q | -65.36% |
Revenue Y/Y | -60.82% |
Profit margin | -204.16% |
Oper. margin | -209.08% |
Gross margin | 82.65% |
EBIT margin | -209.08% |
EBITDA margin | -708.82% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCara Therapeutics stock price history
Cara Therapeutics stock forecast
Cara Therapeutics financial statements
| Jun 2023 | 6.93M | -31.47M | -454.05% |
|---|---|---|---|
| Sep 2023 | 4.86M | -28.03M | -576.08% |
| Dec 2023 | 3.00M | -32.33M | -1076.46% |
| Mar 2024 | 2.13M | -30.69M | -1437.75% |
| Mar 2024 | 2.13M | -30.69M | -1437.75% |
|---|---|---|---|
| Sep 2025 | 800K | -17.97M | -2247.21% |
| Oct 2025 | 800K | -12.55M | -1569.41% |
| Dec 2025 | 600K | -10.91M | -1819.6% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 134389000 | 25.45M | 18.94% |
|---|---|---|---|
| Sep 2023 | 115338000 | 29.69M | 25.75% |
| Dec 2023 | 125844000 | 68.75M | 54.64% |
| Mar 2024 | 90099000 | 60.29M | 66.92% |
| Jun 2023 | -20.44M | 32.80M | 0 |
|---|---|---|---|
| Sep 2023 | -19.64M | 23.15M | 1.11M |
| Dec 2023 | -17.37M | -30.20M | 36.47M |
| Mar 2024 | -30.45M | 25.95M | -685K |
Cara Therapeutics alternative data
| Aug 2023 | 106 |
|---|---|
| Sep 2023 | 106 |
| Oct 2023 | 106 |
| Nov 2023 | 106 |
| Dec 2023 | 106 |
| Jan 2024 | 106 |
| Feb 2024 | 106 |
| Mar 2024 | 55 |
| Apr 2024 | 55 |
| May 2024 | 55 |
| Jun 2024 | 55 |
| Jul 2024 | 55 |
Cara Therapeutics other data
62.39%
+2.02%
of CARA is owned by hedge funds
175
-1
31.64M
+1.38M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 8199 |
| Aug 2023 | 0 | 4307 |
| Nov 2023 | 0 | 3796 |
| Feb 2024 | 0 | 52976 |
| Apr 2024 | 0 | 5506 |
| May 2024 | 0 | 3936 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 3,936 | $0.75 | $2,952 | ||
Sale | GONCALVES JOANA officer: CHIEF ME.. | Common Stock | 2,753 | $0.83 | $2,285 | ||
Sale | TERRILLION SCOTT officer: SEC'Y; C.. | Common Stock | 2,753 | $0.83 | $2,285 | ||
Sale | TERRILLION SCOTT officer: SEC'Y; C.. | Common Stock | 3,293 | $0.89 | $2,931 | ||
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 5,834 | $0.89 | $5,192 | ||
Sale | GONCALVES JOANA officer: CHIEF ME.. | Common Stock | 3,293 | $0.89 | $2,931 | ||
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 35,575 | $0.53 | $18,855 | ||
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 4,981 | $0.55 | $2,740 | ||
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 3,796 | $1.22 | $4,631 | ||
Sale | POSNER CHRISTOPHER director, officer.. | Common Stock | 4,307 | $3.07 | $13,222 |
| Patent |
|---|
Application Filling date: 28 Apr 2021 Issue date: 11 Nov 2021 |
Application Filling date: 18 Mar 2021 Issue date: 23 Sep 2021 |
Grant Filling date: 13 Sep 2019 Issue date: 15 Jun 2021 |
Grant Filling date: 9 Jul 2018 Issue date: 9 Feb 2021 |
Grant Utility: Synthetic peptide amides Filling date: 26 Nov 2018 Issue date: 6 Oct 2020 |
Application Filling date: 13 Sep 2019 Issue date: 19 Mar 2020 |
Application Filling date: 26 Nov 2018 Issue date: 8 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2023 4 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Derek T. Chalmers D.Sc., Ph.D. (1964) Co-Founder & Senior Advisor | $1,020,000 |
Dr. Frédérique Menzaghi (1966) Chief Scientific Officer and Senior Vice President of R&D | $785,510 |
| Dr. Joana Goncalves (1974) Chief Medical Officer | $732,900 |
| Mr. Scott M. Terrillion (1963) Chief Compliance Officer, Gen. Counsel & Corporation Sec. | $587,880 |
| Mr. Richard Makara (1971) Vice President, Head of Accounting, Controller & Principal Accounting Officer | $420,430 |
| Mr. Thomas Charles Reilly (1972) Chief Financial Officer | $170,590 |
| Mr. Christopher A. Posner (1970) Pres, Chief Executive Officer & Director | $57,500 |
Cara Therapeutics: Looking To Place A Bid After A Big Miss On Earnings
InterCure: Why The Company Is Grossly Undervalued By Wall Street
Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Calls A Much Safer Way To Buy Cara Therapeutics
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
Cara Therapeutics: De-Risked And Extremely Attractive
Cara Therapeutics: 200% Upside Possible With FDA Approval
Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Cara Therapeutics: Upcoming PDUFA May See Some Upside
-
What's the price of Cara Therapeutics stock today?
One share of Cara Therapeutics stock can currently be purchased for approximately $5.4.
-
When is Cara Therapeutics's next earnings date?
Unfortunately, Cara Therapeutics's (CARA) next earnings date is currently unknown.
-
Does Cara Therapeutics pay dividends?
No, Cara Therapeutics does not pay dividends.
-
How much money does Cara Therapeutics make?
Cara Therapeutics has a market capitalization of 22.96M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 49.92% to 20.97M US dollars.
-
What is Cara Therapeutics's stock symbol?
Cara Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CARA".
-
What is Cara Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cara Therapeutics?
Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cara Therapeutics's key executives?
Cara Therapeutics's management team includes the following people:
- Dr. Derek T. Chalmers D.Sc., Ph.D. Co-Founder & Senior Advisor(age: 61, pay: $1,020,000)
- Dr. Frédérique Menzaghi Chief Scientific Officer and Senior Vice President of R&D(age: 59, pay: $785,510)
- Dr. Joana Goncalves Chief Medical Officer(age: 51, pay: $732,900)
- Mr. Scott M. Terrillion Chief Compliance Officer, Gen. Counsel & Corporation Sec.(age: 62, pay: $587,880)
- Mr. Richard Makara Vice President, Head of Accounting, Controller & Principal Accounting Officer(age: 54, pay: $420,430)
- Mr. Thomas Charles Reilly Chief Financial Officer(age: 53, pay: $170,590)
- Mr. Christopher A. Posner Pres, Chief Executive Officer & Director(age: 55, pay: $57,500)
-
Is Cara Therapeutics founder-led company?
Yes, Cara Therapeutics is a company led by its founder Dr. Derek T. Chalmers D.Sc., Ph.D..
-
How many employees does Cara Therapeutics have?
As Jul 2024, Cara Therapeutics employs 55 workers.
-
When Cara Therapeutics went public?
Cara Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 31 Jan 2014.
-
What is Cara Therapeutics's official website?
The official website for Cara Therapeutics is caratherapeutics.com.
-
Where are Cara Therapeutics's headquarters?
Cara Therapeutics is headquartered at 4 Stamford Plaza, Stamford, CT.
-
How can i contact Cara Therapeutics?
Cara Therapeutics's mailing address is 4 Stamford Plaza, Stamford, CT and company can be reached via phone at +20 3 4063700.
Cara Therapeutics company profile:
Cara Therapeutics, Inc.
caratherapeutics.comExchange:
NASDAQ
Full time employees:
55
Industry:
Biotechnology
Sector:
Healthcare
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
4 Stamford Plaza
Stamford, CT 06902
Stamford, CT 06902
CIK: 0001346830
ISIN: US1407551092
CUSIP: 140755109
